Zysis Limited

Early Stage

Zysis Limited is a pharmaceutical company that specialises in the re-formulation of existing drugs in new formats for disorders of the Central Nervous System in order to improve sufferers’ lives.  Zysis is currently developing two new treatments.  One is a once-weekly, oral tablet for the treatment of Psychotic conditions or an adjunctive treatment for Major Depressive Disorder (Aripiprazole Oral Once Weekly).  The other is a once-daily, effective formulation for the treatment of speciality Anxiety disorders such as Panic Disorders and Post-Traumatic Stress Disorder (Nocturel).

The Company’s products should offer significant patient benefits and improved compliance, an important factor in the treatment of psychotic conditions.

Our investment has supported the development of the products, with the Company’s re-formulated Aripiprazole product having completed Phase I bioequivalence testing.

Our Approach

What do we look for?

Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.

We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors.

learn more

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200